Clinical Trial Update: Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease [Phase 1]

View source ↗

Summary

Phase 1 study in patients with non-critical coronary artery disease suggests that release of tissue-type plasminogen activator (t-PA) may predict major adverse …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Activase (alteplase)

Snippet

Sponsor: Vanderbilt University | Conditions: Coronary Artery Disease | Phase 1 | Status: TERMINATED